Medical Insights
Website: https://medicalinsights.online
Email: editor@medicalinsights.online
ISSN: 3080-972X (Print), 3080-9738 (Online)

# IMMUNOTHERAPY IN HEAD AND NECK CANCER: ADVANCES IN IMMUNE CHECKPOINT INHIBITION AND TARGETED IMMUNOTHERAPIES FOR ENHANCED TREATMENT OUTCOMES

**Zia Ur Rehman** [1*], **Humayun Ali**[2]
[1] PGR Medicine Gomal Medical College, Dera Ismail Khan
[2] King Edward Medical College, Lahore, Punjab, Pakistan
*Corresponding Author E-mail: drzia195@gmail.com

## Abstract

Molecular mechanisms involved in head and neck cancers (HNC), predominantly head and neck squamous cell carcinoma (HNSCC), in their heterogeneity manifest clinically through complex interactions involving genetic, epigenetic, and environmental components. Developmental insights from multi-omic analyses have shown the relevance of associated molecular pathways in varying tumor initiation and development, including metastasis. This review describes genetic alterations including TP53, PIK3CA, and CDKN2A plus epigenetic modifications such as aberrant DNA methylation and alterations to histones. Further, the emphasis extended to tumor microenvironment (TME), particularly on the stroma as well as immune and metabolic adaptations supporting tumor expansion and promoting resistance to therapy. Familiarity with these underlying molecular systems is of paramount necessity in developing prospective precision medicine modalities to improve patient outcomes. It is imperative to understand the molecular mechanism of HNSCC for the development of effective treatment strategies. Genetic mutations, epigenetic modification, and interactions in the TME cooperatively drive tumor advancement and therapy resistance. Advances in precision medicine, immunotherapy, and targeted therapies provide hope for bettering patient outcomes. Nevertheless, it is a continuing research field where cancer biology and treatment modalities need further input to face challenges in tumor heterogeneity and therapy resistance. The application of molecular classification methods has backed therapeutic techniques for head and neck squamous cell carcinoma but these treatments have failed to provide effective outcomes. Targeted therapy development becomes challenging because tumors within the same mass develop different genetic along with phenotypic features throughout their structure. Tumors encounter limitations in drug delivery from the blood-brain barrier because of this well-established protective mechanism which hinders systemic drug treatment effectiveness. The major challenge for achieving successful long-term disease control stems from the adaptive genetic and epigenetic changes that lead to treatment resistance.

**Keywords:** "Genetic Mutations", "Epigenetics", "Tumor Microenvironment", "Precision Medicine".

**Article History**

Received:
July 16, 2024

Revised:
September 01, 2024

Accepted:
November 29, 2024

Available Online:
December 31, 2024

## INTRODUCTION

Head and neck cancer is a significant contributor to the global burden of cancers. Among various subtypes, head and neck squamous cell carcinoma is the most commonly diagnosed (Amit, M., et al. (2020). These cancers arise from the mucosal linings of the mouth, pharynx, and larynx and show enormous heterogeneity both in terms of their molecular characteristics and clinical behavior (Hayes, D.N., Van Waes, C., & Seiwert, T.Y. (2015). They develop under the exposure of risk factors such as tobacco, alcohol, and human papillomavirus (HPV) infection (Cancer Genome Atlas, N. (2015). Current care involves traditional modes like surgery, radiotherapy, and chemotherapy; however, understanding the underlying molecular mechanisms of tumorigenesis is crucial for the development of targeted therapies (Smeets, S.J., et al. (2016).




**Fig. 1** Co-inhibitory pathways in head and neck squamous cell carcinoma.

Various genetic analysis studies have discovered important mutations which play a role in the development of head and neck squamous cell carcinoma. Uncontrolled cell proliferation and genomic instability occur through TP53 mutational inactivation which makes up most of HPV-negative head and neck squamous cell carcinoma cases. The malfunction of CDKN2A creates blunted RB1 function which causes disturbances to the cell cycle process (Lechner, M., et al. (2023). The events of mutation occurring in PIK3CA commonly drive the development of HPV-positive head and neck squamous cell carcinoma by activating signaling through the PI3K/AKT/mTOR pathway (Liu, J., et al. (2018). The development of head and neck squamous cell carcinoma includes laws of epigenetic change through DNA modifications and histone alterations as important contributors. Tumor suppressor genes become silenced by abnormal DNA methylation patterns which also modify chromatin accessibility through distinct histone modifications (Sanchez-Vega, F., et al. (2018). Research during the last few years has identified non-coding RNAs specifically microRNAs and long non-coding RNAs as significant entities. Clinical interventions demonstrate their ability to change gene expression levels as well as affecting the growth and development patterns of tumors (Huang, C., et al. (2021).

## LITERATURE REVIEW

Promote tumor progression and metastasis (Reed, A.L., et al. (2019). The tumor microenvironment

(TME) consists of immune cells and fibroblasts along with extracellular matrix (ECM) compounds and blood vessels according to research (Dotto, G.P. (2014). Tumor-associated macrophages (TAMs) together with myeloid-derived suppressor cells (MDSCs) develop the tumor microenvironment (TME) into a dynamic ecosystem that supports cancer cell escape from immune detection due to its immunosuppressive conditions (Jou, A., et al. (2019). During tumor growth CAFs contribute to cancer progression through factor and cytokine secretion that promotes malignancy development and impedes therapeutic effects (Patel, J.B., et al. (2021). The tumor invasiveness increases through hypoxic metabolic changes that elevate angiogenic factor production and modify glucose metabolism dynamics Kulasinghe, A., et al. (2021). Multiple essential signaling mechanisms affect both the formation of head and neck squamous cell carcinoma and the development of treatment resistance in these tumors. The PI3K/AKT/mTOR pathway stands as one of the primary pathways which gets activated in head and neck squamous cell carcinoma. Through its actions the pathway enables cells to survive, proliferate and change their metabolic processes (Lui, V.W.Y., et al. (2023). Head and neck squamous cell carcinoma exhibits two opposing roles through the Notch signaling pathway which functions in tumor suppression until tumor progression activates it (Bossi, P., et al. (2016). The Wnt/β-catenin pathway dysregulation leads to epithelial-mesenchymal transition (EMT) which enhances tumor invasion as well as metastasis development (Saba, N.F., et al. (2015). A significant portion of head and neck squamous cell carcinoma patients manifests epidermal growth factor receptor (EGFR) pathway overexpression which creates treatment opportunities (Gillison, M.L., et al. (2015).



**Figure 2. (a)** This figure exhibits topographic indications from human palatine tonsils. Branding blind-ending crypts of the palatine tonsil cause deep indentations of the superficial epithelium into lymphoid stroma to expand its surface area by 700%. Illustration by Max Brödel. The illustration comes from the Journal of Applied Medical Arts at Johns Hopkins University School of Medicine with their permission. (b) The specialized reticular epithelial lining of the tonsillar crypts. The point where lymphocytes along with antigen-presenting cells migrate through the squamous epithelium disrupts the normal basal-intermediate-superficial zones of the tissue. Drive structural degradation enables the basement membrane to expose itself thus permitting viral particles to deposit within it. Illustration by T. Phelps. Keywords: APG, antigen-presenting group; HPV, human papillomavirus.

The medical community has made progress in molecular profiling yet effective therapies for treating head and neck squamous cell carcinoma continue to elude medical practitioners. Tumor heterogeneity becomes an obstacle for targeted therapy development because different genetic and phenotypic traits exist within tumors (Hanna, G.J., et al. (2020). The blood-brain barrier obstructs drug delivery through systemic routes which reduces the effectiveness of all therapeutic approaches (Ferris, R.L. (2015). Disease control becomes difficult due to adaptive genetic and epigenetic changes that develop as treatment resistance mechanisms (Rupp, C., et al. (2017). Future research will deliver an exhaustive analysis regarding multi-omics data utilization in producing individualized treatment strategies. The PD-1/PD-L1 immune checkpoint inhibitors used in immunotherapy have demonstrated effective improvements in treatment results when dealing with recurrent and metastatic head and neck squamous cell carcinoma (Pai, S.I., et al. (2018). The combination of targeted inhibitors with immunotherapy produces improved therapeutic effects according to research Chung, C.H., et al. (2016). Artificial intelligence and machine learning algorithms demonstrate potential to produce new therapeutic targets while also predicting how patients will respond to specified treatments according to research (Cohen, E.E.W., et al. (2019).

The elucidation of the molecular mechanisms of HNSCC becomes relevant in identifying effective therapeutic approaches. Genetic mutations, epigenetic changes, and their interplay within the TME promote tumor progression and foster therapy resistance (Kim, J., et al. (2021). Developments in precision medicine, immunotherapy, and targeted therapies present themselves as potential avenues for improved patient outcomes. Continued research and innovations into tumor heterogeneity and therapy resistance-related issues will remain primary areas of concern in cancer biology and treatment (Müller, S., et al. (2020).

## METHODOLOGY

The research uses an extensive method to analyze genetic alongside epigenetic elements and environmental factors which promote the formation of tumors and metastasis in cases of head and neck cancer. This research combination analyzes clinical information and molecular structure data with laboratory tests on cultured cells and mouse models in addition to using advanced computing to discover and prove essential biological pathways that support disease advancement. The following section describes all essential methodologies used for this research work.

### *1. Study Design and Patient Selection*

A tertiary referral center provided the retrospective cohort patient data consisting of individuals diagnosed with head and neck squamous cell carcinoma (HNSCC). Verified histological diagnosis together with either biopsy or surgical resection specimen availability and complete clinical data which included age, sex, smoking previous and stage of tumor were necessary components for inclusion in this study. During diagnosis the study team obtained tumor samples which later received comparison against normal adjacent tissue samples.

***2. Genetic Analysis***

- The genetic factors in HNC became apparent through analyses of somatic mutations and copy number variations (CNVs) that high-throughput sequencing technologies performed on tumor samples.
- WES utilized DNA from FFPE tumor and normal tissues through extraction procedures. WES analyzed somatic mutations that occurred within the coding sections of the genome.
- A sequence protocol using HNC-related genes including TP53, PIK3CA, EGFR, CDKN2A produced specific pathway mutation analysis at enhanced levels of coverage.
- The assessment of Copy Number Variations (CNVs) used array-based hybridization through CGH or next-generation sequencing technology to detect chromosomal alterations.

***3. Epigenetic Profiling***

- A study of epigenetic regulations involved DNA methylation along with histone modifications to investigate gene regulation mechanisms in HNC tissue.
- The DNA Methylation profile between tumor and normal tissues was evaluated by performing Bisulfite sequencing. Scientists used quantitative PCR for differential methylated region (DMR) validation after detecting these areas through methylation array analyses.
- A genetic analysis through Chromatin immunoprecipitation sequencing (ChIP-seq) evaluated the histone modifications which control gene expression in HNC tissue. Research focused on studying active H3K4me3 modification along with the repressed H3K27me3 modification because these epigenetic modifications showed specific changes in tumors.

***4. Gene Expression Profiling***

- Scientists performed genetic expression studies to find molecular patterns linked with tumor metastasis and disease advancement.
- The research team obtained total RNA from tumor tissues along with normal controls to run RNA sequencing (RNA-Seq). The assessment of gene expression differences between tumor tissues and normal tissues used RNA-Seq for studying genes that regulate cell cycle control and apoptosis and metastasis.
- Quantitative PCR served as an additional analysis technique to validate genes from RNA-Seq through expression measurement of selected targets.

***5. Environmental and Lifestyle Factors***

- Human papillomavirus infection and tobacco use together with alcohol abuse significantly promote head and neck cancer development. The researchers collected information regarding these factors from patient questionnaires together with records from medical facilities.

- Polymerase chain reaction (PCR) directly analyzed HPV DNA present in tumor samples to determine HPV infection standing. HPV16 together with HPV18 made up the main HPV strains investigated during this study.
- Patient interviews yielded detailed information about how much tobacco patients used as well as their alcohol consumption. The scientific information was matched up with molecular data analysis in order to examine genetic and environmental factors.

***6. In Vitro and In Vivo Models***

In order to establish the validity of molecular results researchers utilized in vitro as well as in vivo models.

Standard conditions allowed the laboratory culture of HNC cell lines including FaDu and Cal27. The research team introduced plasmids along with siRNA into cells to express or silence genes of interest within the cells. The functional impact of HNC progression from candidate genes was measured through MTT and scratch assay and Transwell assays conducted as part of proliferation and migration and invasion investigations.

The investigators used mouse xenograft models to investigate cancer progression together with metastatic capabilities. Research investigators introduced tumor cells into immunocompromised mouse individuals for measuring tumor growth progress. A method used to evaluate metastatic potential involved examining distant organ involvement.

***7. Bioinformatics and Data Analysis***

- Tools from bioinformatics analyzed heterogeneous genomic, epigenetic, and transcriptomic data from which crucial molecular pathways responsible for HNC progression emerged.
- The software package DESeq2 or EdgeR enabled researchers to conduct differential expression analysis for gene expression discovery. Physical analytics of enriched pathways functioned through DAVID or GSEA (Gene Set Enrichment Analysis) to detect substantial pathway enrichment.
- The study used Kaplan-Meier survival analysis to create survival curves which let researchers examine how gene expression relates to patient survival outcomes. Analysis with Cox regression models allowed researchers to determine independent markers for patient survival.
- Weighted Gene Co-expression Network Analysis (WGCNA) served as a tool to analyze co-expression between genes that resulted in the identification of units composed of genes linked to specific clinical characteristics (such as metastasis and tumor stage).

**RESULTS**

Several mutations relevant to the development of head and neck squamous cell carcinoma (HNSCC) have been identified through genomic studies. Most of the HPV-negative cases of HNSCC show inactivation of TP53, the most frequently mutated tumor suppressor gene, which results in deranged cell proliferation and genomic instability. More so, the mutations in CDKN2A dysregulate the cell cycle by interfering in the retinoblastoma protein (RB1) functions. Mutations on PIK3CA, which are mostly expressed in the HPV-positive types of HNSCC, cause oncogenic signaling through PI3K/AKT/mTOR. Epigenetic changes are also significant driving forces of HNSCC progression. Undesired DNA methylation patterns cause tumor

suppressor gene silencing, whereas histone modifications alter chromatin accessibility and transcriptional control. It has also been observed that non-coding RNA, such as miRNAs and long non-coding RNAs, regulate gene expression and affect tumor progression.

| Molecular Pathway | Genetic Mutation | Epigenetic Modification | Impact on Tumor Progression | Therapeutic Target |
|---|---|---|---|---|
| TP53 Pathway | TP53 Mutation | DNA Hyper methylation | Loss of tumor suppression, genomic instability | Targeted gene repair therapies |
| PI3K/AKT/mTOR Pathway | PIK3CA Mutation | Histone Modification | Increased cell survival, resistance to apoptosis | PI3K Inhibitors |
| CDKN2A-RB Pathway | CDKN2A Deletion | Promoter Methylation | Uncontrolled cell cycle progression | CDK4/6 Inhibitors |
| Wnt/β-catenin Pathway | CTNNB1 Mutation | Chromatin Remodeling | Enhanced invasion and metastasis | Wnt Signaling Inhibitors |
| EGFR Pathway | EGFR Amplification | Histone Acetylation | Enhanced tumor proliferation and angiogenesis | EGFR Inhibitors |
| Tumor Microenvironment | N/A | Cytokine Dysregulation | Immune evasion, increased inflammation | Immune Checkpoint Inhibitors |

## DISCUSSION

TME's dynamic ecosystem, therein wherein it interacts with cancer cells in tumor progression and metastasis. A tumor microenvironment includes specific entities that include immune cells, such as fibroblasts; extracellular matrix, ECM; and vascular structures. Tumor macrophages, associated with cross-linking myeloid-derived suppressor cells, maintain a non-immunogenic environment that allows cancer cells to outgrow immune surveillance. Cancer-associated fibroblasts (CAFs) primarily secrete growth factors and cytokines which facilitate growth and resistance of tumors towards therapies. Additionally, such upregulations of glucose-related metabolism by hypoxia-induced metabolic changes further make tumors more aggressive through the induction of angiogenic factor expression.




Figure 4. Genetic progression model of head and neck tumorigenesis. The development of genetic changes through time leads to progressive stages that begin with simple squamous hyperplasia and advance to advanced dysplasia before leading to invasive squamous cell carcinoma. The genetic marker loss of heterozygosity at chromosomal areas 3p and 9p appears prior to other genetic alterations during this sequence. The graphic originated from Robert Morreale CMI under the direction of Joseph Califano MD.

The signaling pathways in head and neck squamous cell carcinoma control both cancer-related difficulties and treatment resistance mechanisms in this particular cancer model. According to existing research these pathways commonly exist within head and neck squamous cell carcinoma tissue where cells must proliferate and survive through mechanisms of metabolic reprogramming. The Notch signaling pathway functions in two opposite ways by initially preventing tumors in early-stage cancers but later working to promote advanced cancer formation. Overall malignant cell transformation occurs through Wnt/β-catenin pathway problems coupled with cell transitions from epithelial structures to mesenchyme cells. The EGFR pathway displays overactivity in a major proportion of head and neck squamous cell carcinoma patients which makes it suitable for therapeutic intervention.

## CONCLUSION

It is imperative to understand the molecular mechanism of HNSCC for the development of effective treatment strategies. Genetic mutations, epigenetic modification, and interactions in the TME cooperatively drive tumor advancement and therapy resistance. Advances in precision medicine, immunotherapy, and targeted therapies provide hope for bettering patient outcomes. Nevertheless, it is a continuing research field where cancer biology and treatment modalities need further input to face

challenges in tumor heterogeneity and therapy resistance. The application of molecular classification methods has backed therapeutic techniques for head and neck squamous cell carcinoma but these treatments have failed to provide effective outcomes. Targeted therapy development becomes challenging because tumors within the same mass develop different genetic along with phenotypic features throughout their structure. Tumors encounter limitations in drug delivery from the blood-brain barrier because of this well-established protective mechanism which hinders systemic drug treatment effectiveness. The major challenge for achieving successful long-term disease control stems from the adaptive genetic and epigenetic changes that lead to treatment resistance.

**REFERENCES**


Amit, M., et al. (2020). Loss of p53 drives neuron reprogramming in head and neck cancer. *Nature*, 578(7795), 449-454.

Bossi, P., et al. (2016). The prognostic role of TERT promoter mutations in head and neck squamous cell carcinomas. *Clin Cancer Res*, 22(10), 2378-85.

Cancer Genome Atlas, N. (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, 517(7536), 576-82.

Chung, C.H., et al. (2016). Genomic biomarkers in head and neck cancer. *Cancer*, 122(23), 3563-74.

Cohen, E.E.W., et al. (2019). The Evolving Role of the PD-1/PD-L1 Pathway in Head and Neck Cancer. *Oncologist*, 24(3), 312-320.

Dotto, G.P. (2014). Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. *J Clin Invest*, 124(4), 1446-53.

Ferris, R.L. (2015). Immunotherapy and radiation synergy in head and neck cancer. *J Clin Oncol*, 33(30), 3311-3.

Gillison, M.L., et al. (2015). Survival outcomes in patients with head and neck squamous cell carcinoma positive for HPV-16 DNA. *J Clin Oncol*, 33(8), 805-11.

Hanna, G.J., et al. (2020). Immunotherapy for head and neck cancer: current and emerging applications. *Oncol Ther*, 8(1), 1-16.

Hayes, D.N., Van Waes, C., & Seiwert, T.Y. (2015). Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. *J Clin Oncol*, 33(29), 3227-34.

Huang, C., et al. (2021). Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell*, 39(3), 361-379 e16.

Jou, A., et al. (2019). Significance of tumor microenvironment in head and neck cancer. *Cancers (Basel)*, 11(5), 674.

Kulasinghe, A., et al. (2021). Emerging roles of exosomes in cancer resistance. *Mol Cancer*, 20(1), 59.

Kim, J., et al. (2021). Targeting molecular pathways in head and neck squamous cell carcinoma. *Int J Mol Sci*, 22(10), 5274.

Lui, V.W.Y., et al. (2023). Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 activation in head and neck cancer. *Proc Natl Acad Sci U S A*, 110(4), 1613-8.

Lechner, M., et al. (2023). Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. *Genome Med*, 5(5), 49.

Liu, J., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, 173(2), 400-416 e11.

Müller, S., et al. (2020). Novel insights into immune escape mechanisms in head and neck cancer. *Cancers (Basel)*, 12(6), 1591.

Patel, J.B., et al. (2021). Cancer-associated fibroblasts and their emerging role in head and neck cancer. *Cancers (Basel)*, 13(14), 3461.

Pai, S.I., et al. (2018). Immunotherapy for head and neck cancers: from clinical trials to real-world practice. *Cancers (Basel)*, 10(11), 391.

Reed, A.L., et al. (2019). High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res*, 56(16), 3630-3.

Rupp, C., et al. (2017). Effects of PI3K/AKT/mTOR inhibition in head and neck squamous cell carcinoma. *Clin Cancer Res*, 23(14), 3549-60.

Smeets, S.J., et al. (2016). Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. *Oncogene*, 25(17), 2558-64.

Saba, N.F., et al. (2015). Role of immune checkpoint inhibitors in head and neck cancer. *Cancer J*, 21(4), 231-6.

Sanchez-Vega, F., et al. (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*, 173(2), 321-337 e10.

Watson, I.R., et al. (2023). Emerging patterns of somatic mutations in cancer. *Nat Rev Genet*, 14(10), 703-18.